Evolent Health Management

Management criteria checks 2/4

Evolent Health's CEO is Seth Blackley, appointed in Jan 2011, has a tenure of 13.33 years. total yearly compensation is $8.93M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth €15.39M. The average tenure of the management team and the board of directors is 3.2 years and 3.9 years respectively.

Key information

Seth Blackley

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage	8.8%
CEO tenure	13.3yrs
CEO ownership	0.5%
Management average tenure	3.2yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Seth Blackley's remuneration changed compared to Evolent Health's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$9m	US$783k	-US$142m
Sep 30 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$77m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$8m	US$683k	-US$19m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$7m	US$600k	-US$30m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$261m
Dec 31 2020	US$4m	US$438k	-US$328m
Sep 30 2020	n/a	n/a	-US$515m
Jun 30 2020	n/a	n/a	-US$504m
Mar 31 2020	n/a	n/a	-US$334m
Dec 31 2019	US$3m	US$400k	-US$304m
Sep 30 2019	n/a	n/a	-US$121m
Jun 30 2019	n/a	n/a	-US$107m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$2m	US$400k	-US$53m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$56m
Dec 31 2017	US$2m	US$400k	-US$61m

Compensation vs Market: Seth's total compensation ($USD8.93M) is above average for companies of similar size in the German market ($USD2.59M).

Compensation vs Earnings: Seth's compensation has increased whilst the company is unprofitable.

CEO

Seth Blackley (44 yo)

13.3yrs

Tenure

US$8,931,188

Compensation

Mr. Seth Barrie Blackley serves as Chief Executive Officer at Evolent Health, Inc. since October 1, 2020. He serves as President of True Health Indiana, Inc. (True Health Indiana). Mr. Blackley co-founded...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Seth Blackley	Co-Founder	13.3yrs	US$8.93m	0.53% $ 15.4m
Dan McCarthy	CEO of New Century Health & President	1.7yrs	US$5.76m	0.21% $ 6.1m
John Johnson	Chief Financial Officer	4.8yrs	US$3.53m	0.13% $ 3.8m
Emily Rafferty	Chief Operating Officer	less than a year	US$2.69m	0.035% $ 1.0m
Jonathan Weinberg	Chief Legal Officer	10.3yrs	US$2.01m	0.10% $ 3.0m
Aammaad Shams	Chief Accounting Officer	3.9yrs	US$634.88k	0.017% $ 495.7k
Robert Cruz	Chief Technology Officer	no data	no data	no data
Jessica White	Chief Information Officer	less than a year	no data	no data
Seth Frank	Vice President of Investor Relations	2.4yrs	no data	no data
Kali Beyah	Chief People & Brand Officer	2.3yrs	no data	no data
John Tam	Chief Strategy Officer	12.3yrs	no data	no data
Scott Pritchard	President of Performance Suite	no data	no data	no data

3.2yrs

Average Tenure

39.5yo

Average Age

Experienced Management: 9EH's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Seth Blackley	Co-Founder	6.1yrs	US$8.93m	0.53% $ 15.4m
Peter Grua	Independent Director	4.3yrs	US$260.25k	0.032% $ 928.0k
Richard Jelinek	Independent Director	less than a year	US$245.50k	0.0015% $ 42.7k
Russell Glass	Independent Director	less than a year	no data	0.0053% $ 152.1k
Cheryl Scott	Independent Chairperson of the Board & Lead Independent Director	8.5yrs	US$347.75k	0.034% $ 975.0k
Diane Holder	Independent Director	12.8yrs	US$265.25k	0.048% $ 1.4m
Mary Duffy	Independent Director	6.7yrs	US$255.25k	0.015% $ 426.2k
Kim Keck	Independent Director	3.3yrs	US$265.25k	0.014% $ 408.3k
Craig Barbarosh	Independent Director	3.4yrs	US$257.50k	0.015% $ 432.8k
Toyin Ajayi	Independent Director	less than a year	US$195.83k	0% $ 0

3.9yrs

Average Tenure

58yo

Average Age

Experienced Board: 9EH's board of directors are considered experienced (3.9 years average tenure).

Evolent Health Management

Management criteria checks 2/4

Key information

Recent management updates

Evolent Health, Inc., Annual General Meeting, Jun 06, 2024

High number of new directors

Evolent Health, Inc. Appoints Toyin Ajayi to Its Board of Directors

Evolent Health, Inc. Announces Executive Changes

Evolent Health, Inc., Annual General Meeting, Jun 08, 2023

High number of new directors

Recent updates

Evolent Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$1.28 loss per share (vs US$0.20 loss in FY 2022)

Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Evolent Health, Inc., Annual General Meeting, Jun 06, 2024

Evolent Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2024

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2023 and Full Year 2023

Third quarter 2023 earnings released: US$0.30 loss per share (vs US$0.022 profit in 3Q 2022)

Evolent Health, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Insider selling

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.046 loss in 2Q 2022)

Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023 and Reiterates Earnings Guidance for the Full Year Ending December 31, 2023

High number of new directors

Evolent Health, Inc. Appoints Toyin Ajayi to Its Board of Directors

Evolent Health, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Evolent Health, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: US$0.20 loss per share (vs US$0.35 loss in FY 2021)

Evolent Health, Inc., Annual General Meeting, Jun 08, 2023

Evolent Health, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Evolent Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.022 (vs US$0.15 loss in 3Q 2021)

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Evolent Health, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Saxena White P.A. Announces Proposed Settlement in Evolent Health, Inc. Securities Litigation

Evolent Health, Inc. Announces Executive Changes

Lead Independent Director recently sold €113k worth of stock

High number of new directors

Chief Financial Officer recently sold €618k worth of stock

Second quarter 2022 earnings released: US$0.046 loss per share (vs US$0.11 loss in 2Q 2021)

Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022

First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.13 loss in 1Q 2021)

Evolent Health, Inc. Provides Unaudited Earnings Guidance for the Second Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022

Evolent Health, Inc. to Report Q1, 2022 Results on May 04, 2022

Evolent Health, Inc. Announces Changes to Board of Directors, Adds Michael Mentesana and Elevates Frank Williams to Chairman Role

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2024

Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2022 and Full Year Ending December 31, 2022

Evolent Health, Inc., Annual General Meeting, Jun 09, 2022

High number of new directors

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.44 loss in 3Q 2020)

Evolent Health, Inc. (NYSE:EVH) entered into a definitive agreement to acquire Vital Decisions, LLC from Windrose Health Investors III, L.P., fund managed by WindRose Health Investors, LLC for $130 million.

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$2.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.93 loss in 1Q 2020)

Evolent Health, Inc. Provides Revenue Guidance for the Second Quarter and Full Year of Fiscal Year Ending December 31, 2021

Full year 2020 earnings released: US$3.94 loss per share (vs US$3.67 loss in FY 2019)

Revenue beats expectations

New 90-day high: €16.90

Evolent Health, Inc., Annual General Meeting, Jun 10, 2021

Evolent Health, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €15.40

Evolent Health, Inc. Announces Executive Appointments

New 90-day high: €13.90

Evolent Health, Inc. Appoints Craig Barbarosh to Board of Directors as A Class III Director and to the Strategy Committee and Compensation Committee

New 90-day high: €12.80

New 90-day high: €12.20

Revenue beats expectations

Third quarter 2020 earnings released: US$0.44 loss per share

Evolent Health's Subsidiary New Century Health to Support Florida Blue Medicare with Comprehensive Oncology Management Services

New 90-day low: €8.80

New 90-day high - €11.90

Evolent Health, Inc. announced that it expects to receive $32.8 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation